CompanyGraph
What stands out
- Earnings significantly exceed cash generation
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $9.89M, lower than 95% of all stocks globally
- PositionProfit margin is 871%, higher than 95% of its Biotechnology peers (median -45.7%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Earnings significantly exceed cash generation
Financials view
Market Capitalization
701.32MUSDvs all stocks (USD)
Trailing P/E
8.50xvs Biotechnology peers
Revenue (TTM)
9.89MUSDvs all stocks (USD)
Profit Margin
871.02%vs Biotechnology peers
Beta
2.55xvs all stocks
52-Week Change
166.21%vs all stocks
Market Capitalization
701.32MUSDvs all stocks (USD)
Enterprise Value
792.61MUSDvs all stocks (USD)
Trailing P/E
8.50xvs Biotechnology peers
Forward P/E
-62.52xvs Biotechnology peers
PEG Ratio
-0.0362xvs Biotechnology peers
Price to Sales (TTM)
70.89xvs Biotechnology peers
Enterprise to Revenue
80.12xvs Biotechnology peers
Enterprise to EBITDA
-7.60xvs Biotechnology peers
Gross Margin
94.07%vs Biotechnology peers
Profit Margin
871.02%vs Biotechnology peers
Operating Margin
-176.09%vs Biotechnology peers
Return on Assets (TTM)
-25.24%vs Biotechnology peers
Revenue (TTM)
9.89MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.1480USDUpdated Jul 19, 2026Gross Profit (TTM)
-18.84MUSDvs all stocks (USD)
EBITDA (TTM)
-104.33MUSDvs all stocks (USD)
Net Income (TTM)
84.01MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-94.76MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-122.80MUSDvs all stocks (USD)
Pre-tax Income
-2.80MUSDFY2025 · Dec 31, 2025Income Tax Expense
2.01MUSDFY2025 · Dec 31, 2025Net Income
-3.35MUSDFY2025 · Dec 31, 2025EBIT
-122.80MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-236.78MUSDFY2025 · Dec 31, 2025Research & Development
81.30MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
41.50MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
5.06MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.0500USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.0500USDFY2025 · Dec 31, 2025Basic Shares Outstanding
63.51MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
63.51MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-3.35MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-877.00KUSDFY2025 · Dec 31, 2025Free Cash Flow
-240.81MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
9.66MUSDFY2025 · Dec 31, 2025Income Tax Paid
153.00KUSDFY2025 · Dec 31, 2025Interest Paid
35.42MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-3.35MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
964.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
8.19MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-37.13MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
30.45MUSDFY2025 · Dec 31, 2025Capital Expenditures
239.94MUSDFY2025 · Dec 31, 2025Purchase of Investments
-185.31MUSDFY2025 · Dec 31, 2025Sale of Investments
109.90MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
164.52MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-89.16MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Net Financing Cash Flow
-49.82MUSDFY2025 · Dec 31, 2025Shares Outstanding
72.00MSharesUpdated Jul 19, 2026Float Shares
69.80MSharesUpdated Jul 19, 2026Shares Short
15.14MSharesUpdated Jul 19, 2026Short Ratio
6.21daysvs all stocks
Short % of Shares Outstanding
21.68%vs all stocks
% Held by Insiders
3.56%vs all stocks
% Held by Institutions
44.64%vs all stocks
Total Cash (MRQ)
135.32MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.87USDUpdated Jul 19, 2026Total Debt (MRQ)
226.61MUSDvs all stocks (USD)
Current Ratio (MRQ)
3.03xvs Biotechnology peers
Book Value per Share (MRQ)
-0.8800USDUpdated Jul 19, 2026Total Assets
325.63MUSDvs all stocks (USD)
Total Current Assets
215.67MUSDFY2025 · Dec 31, 2025Total Liabilities
446.86MUSDFY2025 · Dec 31, 2025Total Non-current Assets
109.97MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
368.80MUSDFY2025 · Dec 31, 2025Total Current Liabilities
78.06MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
9.66MUSDFY2025 · Dec 31, 2025Other Short-term Investments
162.14MUSDFY2025 · Dec 31, 2025Accounts Receivable
6.44MUSDFY2025 · Dec 31, 2025Accounts Payable
4.76MUSDFY2025 · Dec 31, 2025Short-term Debt
23.36MUSDFY2025 · Dec 31, 2025Deferred Revenue
2.47MUSDFY2025 · Dec 31, 2025Other Current Liabilities
20.55MUSDFY2025 · Dec 31, 2025Long-term Debt
215.78MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
147.32MUSDFY2025 · Dec 31, 2025Common Stock (Book)
716.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-913.70MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
-121.23MUSDvs all stocks (USD)
52-Week Low
3.37USDUpdated Jul 19, 202652-Week High
17.65USDUpdated Jul 19, 202652-Week Change
166.21%vs all stocks
Beta
2.55xvs all stocks
50-Day MA
10.92USDUpdated Jul 19, 2026200-Day MA
10.66USDUpdated Jul 19, 2026Avg 10-Day Volume
1.36MSharesUpdated Jul 19, 2026Avg 30-Day Volume
2.07MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
1.14USDUpdated Jul 19, 2026Other Income / Expense
114.94MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Profit margin is 871%, higher than 95% of its Biotechnology peers (median -45.7%)Significant
Profit margin: 8.71Industry median: -0.46Industry P95: 0.43Peers compared: 261
Structural Tensions
Earnings significantly exceed cash generationSignificant
Net Income (USD, TTM): 84,006,000Operating Cash Flow (USD, TTM): -94,759,000
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $9.89M, lower than 95% of all stocks globallySignificant
Revenue (USD): 9,893,000Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Fuan Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Obio Technology (Shanghai) Corp., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Revenio Group Oyj
Tier 1ProductionApproval-Gated PipelineRule
Hvsen Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ars Pharmaceuticals Inc
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Minsheng Healthcare Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ceribell, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shandong Keyuan Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shenzhen Lifotronic Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Wecome Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking